Intestinal Research

One-year effectiveness and safety of ustekinumab treatment in patients with ulcerative colitis: an Asan-Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD) multicenter real-world cohort study: Ji Eun Baek, Min Kyu Kim, Eun Soo Kim, Kyeong Ok Kim, Hyeong Ho Jo, Sung Wook Hwang, Sang Hyoung Park, Byung Ik Jang, Eun Young Kim, Sung Kook Kim, Suk-Kyun Yang, Byong Duk Ye; Received October 12, 2025 Accepted December 30, 2025 Published online April 20, 2026; DOI: https://doi.org/10.5217/ir.2025.00258 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub: Background/Aims
This study aimed to evaluate the 1-year effectiveness and safety of ustekinumab (UST) in Korean patients with ulcerative colitis (UC).
Methods
We conducted a multicenter retrospective study of UC patients who received UST between January 2021 and October 2023. The primary endpoint was clinical remission at week (W) 8. Secondary endpoints included clinical remission at W16–20 and W52–56; corticosteroid-free clinical remission at W8, W16–20, and W52–56; clinical response at the same time points; endoscopic remission at W16–20 and W52–56; UST interval shortening and persistence through W52–56; and adverse events (AEs).
Results
Sixty patients were included. After excluding one patient in clinical remission at baseline, 49.2% (29/59) achieved clinical remission at W8. Clinical remission rates were 59.3% (35/59) at W16–20 and 55.9% (33/59) at W52–56. Endoscopic remission was achieved in 15.3% (9/59) at W16–20 and 11.9% (7/59) at W52–56. The 12-month UST persistence rate was 84.9%. Multivariable analysis identified factors associated with clinical remission at W52–56: higher body mass index at baseline (adjusted odds ratio [aOR], 1.26; 95% confidence interval [CI], 1.00–1.57; P< 0.05), concomitant immunomodulator use (aOR, 4.69; 95% CI, 1.04–21.06; P= 0.04), and endoscopic improvement at W16–20 (aOR, 13.47; 95% CI, 2.87–63.30; P< 0.01), while prior exposure to advanced therapies was associated with lower remission (aOR, 0.20; 95% CI, 0.04–0.98; P< 0.05). AEs occurred in 24 patients (40.0%), with 1 serious AE (1.7%).
Conclusions
UST showed favorable 1-year effectiveness and an acceptable safety profile in Korean patients with UC.

852 View
46 Download

IBD

Clinical characteristics and long-term disease course in patients with Crohn’s disease as diagnosed by video capsule endoscopy: a multicenter retrospective matched case-control study: June Hwa Bae, Su Hyun Park, Jung-Bin Park, Ji Eun Baek, Seung Wook Hong, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Kyeong Ok Kim, Byung Ik Jang, Mi Rae Lee, Eun Soo Kim, Sang Hyoung Park; Intest Res 2025;23(3):290-301. Published online August 29, 2024; DOI: https://doi.org/10.5217/ir.2024.00056

Abstract PDF PubReader ePub: Background/Aims
Video capsule endoscopy is rarely used to diagnose Crohn’s disease in patients with negative ileocolonoscopy or cross-sectional image findings. We evaluated clinical characteristics and long-term outcomes of these rare cases.
Methods
This multicenter study included patients with Crohn’s disease from 3 tertiary hospitals from January 2007 to October 2022. Patients with normal findings on ileocolonoscopy and computed tomography (CT)/magnetic resonance (MR) enterography but had ulcerations at the small bowel detected by video capsule endoscopy were included. The controls were patients with abnormal findings on endoscopy or CT/MR enterography. Controls were case-matched in a ratio of 3:1 for sex, calendar year of diagnosis, and age at diagnosis.
Results
Among 3,752 patients, 24 (0.6%) were diagnosed with Crohn’s disease using video capsule endoscopy findings. The disease location (P< 0.001) and behavior at diagnosis (P= 0.013) of the cases significantly differed from that of controls. The perianal fistula modifier (25.0% vs. 33.3%, P= 0.446) did not differ significantly between the 2 groups. Initial disease activity and C-reactive protein and fecal calprotectin levels were significantly lower in cases versus controls. The median Lewis score was 838 (interquartile range, 393–1,803). Over 10 years of follow-up, the cases showed significantly lower cumulative risk of complicated behavior, biologics use, Crohn’s disease-related hospitalization, and surgeries (log-rank test P< 0.05).
Conclusions
Patients with Crohn’s disease whose lesions were observed only by video capsule endoscopy were rare, and exhibit different clinical characteristics and a more favorable long-term disease course compared to those who were conventionally diagnosed.

6,673 View
256 Download

IBD

Diagnosis, management, and prevention of infectious complications in inflammatory bowel disease: variations among Asian countries: Ji Eun Baek, Sung Wook Hwang; Intest Res 2023;21(3):277-279. Published online July 27, 2023; DOI: https://doi.org/10.5217/ir.2023.00076

PDF PubReader ePub

Citations

Citations to this article as recorded by

Elderly-onset inflammatory bowel disease in Asia: clinical characteristics and therapeutic strategies
Jiyoung Yoon, Daein Kim, You Sun Kim
Intestinal Research.2025; 23(4): 430. CrossRef

4,377 View
105 Download
1 Web of Science
1 Crossref

Search